CLU and colon cancer. The dual face of CLU: from normal to malignant phenotype.
about
Identification of novel tumor-associated cell surface sialoglycoproteins in human glioblastoma tumors using quantitative proteomicsTumor biomarker glycoproteins in the seminal plasma of healthy human males are endogenous ligands for DC-SIGN.Zinc sensing receptor signaling, mediated by GPR39, reduces butyrate-induced cell death in HT29 colonocytes via upregulation of clusterin.Molecular characterization of circulating tumor cells in human metastatic colorectal cancerA global view of the oncogenic landscape in nasopharyngeal carcinoma: an integrated analysis at the genetic and expression levels.Protein biomarkers distinguish between high- and low-risk pediatric acute lymphoblastic leukemia in a tissue specific manner.Plasma clusterin as a candidate pre-diagnosis marker of colorectal cancer risk in the Florence cohort of the European Prospective Investigation into Cancer and Nutrition: a pilot study.Clinical predictive circulating peptides in rectal cancer patients treated with neoadjuvant chemoradiotherapy.A classification framework applied to cancer gene expression profiles.Clusterin is a gene-specific target of microRNA-21 in head and neck squamous cell carcinoma.MicroRNA Dysregulation in Colon Cancer Microenvironment Interactions: The Importance of Small Things in Metastases.Clusterin, a gene enriched in intestinal stem cells, is required for L1-mediated colon cancer metastasis.Lunasin induces apoptosis and modifies the expression of genes associated with extracellular matrix and cell adhesion in human metastatic colon cancer cells.Aberrant gene expression in mucosa adjacent to tumor reveals a molecular crosstalk in colon cancer.
P2860
Q28544645-6795560E-7ED4-40D0-94A9-773F6702051AQ31031940-2121E49E-1242-4E06-B258-4CED3CFEBCF4Q34251123-39AC6066-0892-4B09-BFD3-9BF34B50109DQ34343518-AA398FED-DB6F-4511-93F8-DA17903E6F4DQ34345591-A45DF847-41E0-42A8-9D3C-8F05BF7055BCQ34816101-0B77D3B8-F9A7-49BB-B9F2-90F48FE930DDQ35101910-EF91022C-C67F-42FC-B10C-B88E27094E68Q35529674-31C00462-F958-4E67-8BAC-445739EB7CD5Q37416138-A2C4AD78-5F0D-48C8-B3EF-D051591F5681Q37673301-5624A95F-4232-4B88-B14C-6643BCFDAB87Q37930489-76F1A691-4595-48C8-9038-F0048BA03AD8Q38259980-E97EBD8C-4B08-4D22-A830-353BE3CB300FQ39564939-E3DAC56E-3FDB-4C9A-9863-D9A6F10213CCQ39682144-DFDBE93E-0E0D-48AC-95CA-D7B8B04A3593
P2860
CLU and colon cancer. The dual face of CLU: from normal to malignant phenotype.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on January 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
CLU and colon cancer. The dual face of CLU: from normal to malignant phenotype.
@en
CLU and colon cancer. The dual face of CLU: from normal to malignant phenotype.
@nl
type
label
CLU and colon cancer. The dual face of CLU: from normal to malignant phenotype.
@en
CLU and colon cancer. The dual face of CLU: from normal to malignant phenotype.
@nl
prefLabel
CLU and colon cancer. The dual face of CLU: from normal to malignant phenotype.
@en
CLU and colon cancer. The dual face of CLU: from normal to malignant phenotype.
@nl
P1476
CLU and colon cancer. The dual face of CLU: from normal to malignant phenotype
@en
P2093
P Mazzarelli
P356
10.1016/S0065-230X(09)05003-9
P577
2009-01-01T00:00:00Z